Aicuris Gmbh + Co. Kg.

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Bayer Aktiengesellschaft

Aicuris Anti-infective Cures Gmbh

Institute of Molecular & Cell Biology

Aic246 Ag & Co. Kg

Aicuris Gmbh & Co. Hk

Holger Zimmermann

Kerstin Henninger

Dieter Lang

Tobias Wunberg

Mario Jeske

Rudolf Schohe-Loop

Guy Hewlett

Rolf Grosser

Judith Baumeister

Susanne Nikolic

Peter Nell

Thomas Lampe

Jörg Keldenich

Ulrich Betz

Martin Radtke

Joerg Keldenich

Martin Hendrix

Kai Thede

Chantal Fuerstner

Frank Süβmeier

Daniela Paulsen

Armin Kern

Ulrich Rosentreter

Siegfried Raddatz

Gunter Schmidt

Wolfgang Bender

Tse-I Lin

Dirk Heimbach

Peter Eckenberg

Joachim Schuhmacher

Bernd Riedl

Marcus Bauser

Dagmar Karthaus

Gerald Kleymann

Niels Svenstrup

Pol Boudes

Thomas Roelle

Alexander Birkmann

David Brueckner

Jürgen Reefschläger

Frank Suessmeier

Juergen Reefschlaeger

Sabine Hallenberger

Susan Zeun

Franz Zumpe

Thomas Krämer

Frank Süssmeier

Johannes Koebberling

Mark O'Connor

Andreas Goeller

David Brückner

Jan Endrikat

Susanne Parke

Jan Nedrikat

Angelo Secci

Peter Lischka

Tamara Pfaff

Frank Süßmeier

Lin Tse-I

Chantal FÜRSTNER

Thomas Kraemer

The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

Substituted dihydroquinazolines

The invention relates to heterocyclylamide-substituted thiazoles, pyrroles and thiophenes and processes for their preparation, to pharmaceutical compositions containing them, and to their use for the treatment and/or prophylaxis of diseases, in particular for the use as antiviral agents, especially against cytomegaloviruses.

Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes

The invention relates to the use, optionally together with oral contraception, of estradiol valerate or 17&#x3b2;-estradiol in combination with 17&#x3b1;-cyanomethyl-17-&#x3b2;-hydroxyestra-4,9-dien-3-one (dienogest) in a multistage or single-stage combination preparation for oral therapy to maintain and/or increase feminine libido. The total number of daily dose units of the multistage combination and of a pharmaceutically harmless placebo or a single-stage combination and optionally the pharmaceutically harmless placebo-containing or placebo- and hormone-free daily dose units amounts to 28 daily dose units.

Use of estradiol valerate or 17&#x3b2;-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido

The invention relates to heterocyclyl-substituted dihydroquinazolines of formula (I), to processes for their preparation, to medicaments containing them, and to methods for the treatment and/or prophylaxis of diseases, in particular, for use as anti-viral agents, in particular, against cytomegaloviruses.

Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents

The invention relates to substituted arylsulfonamides of formula (I) and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses. 

Substituted arylsulfonamides as antiviral agents

The invention relates to substituted dihydroquinazolines and to a method for the production thereof, the use thereof for treating and/or preventing diseases and for producing drugs for treating and/or preventing diseases, in particular for the use of the inventive dihydroquinazolines in the form of antiviral agents, in particular against cytomegaloviruses.

Substituted dihydroquinazolines II

This invention relates to substituted azaquinazolines, to a process for their preparation, to pharmaceutical compositions containing them, and to their use for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.

Substituted azaquinazolines having an antiviral action

The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or &#x3c;3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or &#x3c;2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or &#x3c;2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or &#x3c;1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.

Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

The invention relates to substituted quinolones and to methods for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.

Substituted quinolones III

The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.

2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses

The invention relates to heterocyclylamide-substituted imidazoles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular for the use as antiviral agents, especially against cytomegaloviruses.

Heterocyclyamide-substituted imidazoles

The invention relates to substituted quinolones and to processes for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.

Substituted quinolones

The invention relates to the substituted imidazoles of formula (I) and to methods for producing the same, to their use in the treatment and/or prophylaxis of diseases and to their use for producing drugs for use in the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, especially against cytomegaloviruses.

Antiviral 4-aminocarbonylamino-substituted imidazole compounds

Growing community of inventors

Wuppertal, Germany

Holger Zimmermann